The Lancet Respiratory Medicine

The Lancet Respiratory Medicine is a monthly peer-reviewed medical journal published by Elsevier, founded in 2013 as a specialty title in the Lancet family, covering respiratory medicine and critical care, with a 2025 Journal Impact Factor of 34.7《柳叶刀：呼吸医学》是（Elsevier）出版的月刊同行评审医学期刊，2013 年创刊，为（The Lancet）家族旗下的专科刊物，涵盖呼吸医学与危重症医学，2025 年影响因子为 34.7。

Scope

• It delivers comprehensive, clinically focused coverage of all areas of respiratory medicine and critical care该刊就呼吸医学与危重症医学的所有领域提供全面且聚焦临床的报道。
• Topics it covers include COPD, asthma, cystic fibrosis, idiopathic pulmonary fibrosis, pneumonia, tuberculosis, sarcoidosis, pulmonary hypertension, sleep medicine, lung cancer, tobacco control and palliative medicine其报道主题包括慢性阻塞性肺疾病、哮喘、囊性纤维化、特发性肺纤维化、肺炎、结核病、结节病、肺动脉高压、睡眠医学、肺癌、烟草控制与姑息医学。
• Each monthly issue contains Original Research, Reviews, Personal Views, Comments and News每期月刊载有原创研究、综述、个人观点、评论与新闻。
• Its content is stringently edited and peer-reviewed to ensure scientific merit and clinical relevance其内容经过严格编辑与同行评审，以确保科学价值与临床相关性。
• Original Research is fast-tracked to publication within about eight weeks of submission on average原创研究平均在投稿后约八周内快速发表。
• Accepted papers are published Online First before they are collected into a print issue录用论文先在线提前发布，随后收入印刷版刊期。

History

• It was established in 2013 as a specialty journal in the Lancet group, and its first issue appeared in March 2013该刊于 2013 年作为（The Lancet）集团旗下的专科期刊创刊，首期于 2013 年 3 月出版。
• It was launched during the Lancet Group's expansion into specialty medicine, alongside titles such as The Lancet Oncology and The Lancet Neurology该刊创刊于（The Lancet）集团向专科医学拓展的进程中，同期专科刊还有（The Lancet Oncology）与（The Lancet Neurology）等。
• Emma Grainger, who has worked in the Lancet group since 2005, led the launch as founding Editor-in-Chief自 2005 年起在（The Lancet）集团任职的 Emma Grainger 作为创刊主编主持了该刊的创办。
• It is published by Elsevier, which has owned and published the Lancet group since 1991该刊由（Elsevier）出版，后者自 1991 年起拥有并出版（The Lancet）集团。
• It published a widely cited 2020 study of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China该刊 2020 年发表了关于中国武汉（SARS-CoV-2）肺炎危重症患者的一项被广泛引用的研究。^[1]
• Its 2025 Journal Impact Factor is 34.7, ranking first among 107 respiratory system journals and first among 66 critical care journals其 2025 年影响因子为 34.7，在 107 种呼吸系统期刊与 66 种危重症医学期刊中均排名第一。

Editors

• The Editor-in-Chief is Emma Grainger, who has worked in the Lancet group since 2005现任主编为 Emma Grainger，自 2005 年起在（The Lancet）集团任职。
• The Deputy Editor is Diana Stanley, a physician by training who joined the journal's inaugural team in 2012 and is based in the New York office副编辑为 Diana Stanley，她受过医师训练，2012 年加入该刊创刊团队，现驻纽约办公室。
• It maintains an international editorial board and a team of professional editors该刊设有国际化编委会与一支专业编辑团队。
• Every article is stringently edited and peer-reviewed by external experts每篇文章均经严格编辑并由外部专家进行同行评审。
• Each monthly issue is curated by the editorial team and its Original Research is fast-tracked to publication每期月刊由编辑团队统筹编排，其原创研究实行快速发表。
• It is part of the Lancet Group, a family of specialty journals that share editorial standards and advocacy该刊隶属（The Lancet）集团，这一专科期刊家族共享编辑标准与主张。